{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:07:22Z","timestamp":1778288842762,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018711","name":"Second Affiliated Hospital of Harbin Medical University","doi-asserted-by":"publisher","award":["2023YQB018"],"award-info":[{"award-number":["2023YQB018"]}],"id":[{"id":"10.13039\/100018711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["CSTB2023NSCQ-ZDJ0013"],"award-info":[{"award-number":["CSTB2023NSCQ-ZDJ0013"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clgc.2024.102262","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T12:47:47Z","timestamp":1730465267000},"page":"102262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Transcriptome-Based Network Analysis Related to Histone Deacetylase Genes and Identified EMP1 as a Potential Biomarker for Prognosis in Bladder Cancer"],"prefix":"10.1016","volume":"23","author":[{"given":"Qiong","family":"Bao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clgc.2024.102262_bib0001","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: a systematic review of risk factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102262_bib0002","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","article-title":"Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice","volume":"20","author":"van Hoogstraten","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102262_bib0003","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","article-title":"Progress in systemic therapy for advanced-stage urothelial carcinoma","volume":"21","author":"Nadal","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102262_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116324","article-title":"Synergistic therapeutics: co-targeting histone deacetylases and ribonucleotide reductase for enhanced cancer treatment","volume":"269","author":"Shetty","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"6","key":"10.1016\/j.clgc.2024.102262_bib0005","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.molonc.2012.07.003","article-title":"Histone deacetylases and cancer","volume":"6","author":"Barneda-Zahonero","year":"2012","journal-title":"Mol Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102262_bib0006","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3390\/ijms20061291","article-title":"Revisiting histone deacetylases in human tumorigenesis: the paradigm of urothelial bladder cancer","volume":"20","author":"Giannopoulou","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clgc.2024.102262_bib0007","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1756-8722-4-17","article-title":"Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer","volume":"4","author":"Xu","year":"2011","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2024.102262_bib0008","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/s41416-023-02195-0","article-title":"Selective inhibition of HDAC6 promotes bladder cancer radio sensitization and mitigates the radiation-induced CXCL1 signalling","volume":"128","author":"Tsai","year":"2023","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.clgc.2024.102262_bib0009","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.3390\/ijms20092135","article-title":"HDAC5 expression in urothelial carcinoma cell lines inhibits long-term proliferation but can promote epithelial-to-mesenchymal transition","volume":"20","author":"Jaguva Vasudevan","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.clgc.2024.102262_bib0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s13577-019-00237-5","article-title":"SIRT1 promotes GLUT1 expression and bladder cancer progression via regulation of glucose uptake","volume":"32","author":"Chen","year":"2019","journal-title":"Hum Cell"},{"issue":"6","key":"10.1016\/j.clgc.2024.102262_bib0011","doi-asserted-by":"crossref","first-page":"541","DOI":"10.15537\/smj.2019.6.24248","article-title":"Overexpression of SIRT1 in urothelial carcinoma of the urinary bladder is associated with local recurrence and poor survival","volume":"40","author":"Al-Maghrabi","year":"2019","journal-title":"Saudi Med J"},{"issue":"3","key":"10.1016\/j.clgc.2024.102262_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264527","article-title":"An HDAC9-associated immune-related signature predicts bladder cancer prognosis","volume":"17","author":"Fu","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2024.102262_bib0013","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1741-7015-8-21","article-title":"Reporting performance of prognostic models in cancer: a review","volume":"8","author":"Mallett","year":"2010","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.clgc.2024.102262_bib0014","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.eururo.2022.02.028","article-title":"Prognostic and predictive value of fibroblast growth factor receptor alterations in high-grade non-muscle-invasive bladder cancer treated with and without bacillus Calmette-Gu\u00e9rin immunotherapy","volume":"81","author":"Mayr","year":"2022","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102262_bib0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.eururo.2017.05.040","article-title":"Prognostic impact of a 12-gene progression score in non-muscle-invasive bladder cancer: a prospective multicentre validation study","volume":"72","author":"Dyrskj\u00f8t","year":"2017","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.clgc.2024.102262_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007466","article-title":"Machine learning-based integration develops a metabolism-derived consensus model for improving immunotherapy in pancreatic cancer","volume":"11","author":"Guo","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"7693","key":"10.1016\/j.clgc.2024.102262_bib0017","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clgc.2024.102262_bib0018","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/s41467-024-45479-6","article-title":"Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"issue":"10364","key":"10.1016\/j.clgc.2024.102262_bib0019","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments","volume":"400","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clgc.2024.102262_bib0020","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2024.102262_bib0021","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"10061","key":"10.1016\/j.clgc.2024.102262_bib0022","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2024.102262_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115938","article-title":"Dual inhibitors of hdac and other epigenetic regulators: a novel strategy for cancer treatment","volume":"263","author":"Shirbhate","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.clgc.2024.102262_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1193637","article-title":"HDAC-an important target for improving tumor radiotherapy resistance","volume":"13","author":"Ling","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2024.102262_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116129","article-title":"HDAC-targeting epigenetic modulators for cancer immunotherapy","volume":"265","author":"Cheng","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.clgc.2024.102262_bib0026","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41698-024-00562-5","article-title":"Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal adenocarcinoma","volume":"8","author":"Atri","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102262_bib0027","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13046-023-02930-8","article-title":"HDAC1\/2 control mesothelium\/ovarian cancer adhesive interactions impacting on Talin-1-\u03b15\u03b21-integrin-mediated actin cytoskeleton and extracellular matrix protein remodeling","volume":"43","author":"Terri","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.clgc.2024.102262_bib0028","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s10620-023-08215-6","article-title":"SOX4\/HDAC2 axis enhances cell survivability and reduces apoptosis by activating AKT\/MAPK signaling in colorectal cancer","volume":"69","author":"Chakraborty","year":"2024","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10.1016\/j.clgc.2024.102262_bib0029","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12032-022-01770-4","article-title":"Differential molecular mechanistic behavior of HDACs in cancer progression","volume":"39","author":"Singh","year":"2022","journal-title":"Med Oncol"},{"key":"10.1016\/j.clgc.2024.102262_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104100","article-title":"DNTTIP1 promotes nasopharyngeal carcinoma metastasis via recruiting HDAC1 to DUSP2 promoter and activating ERK signaling pathway","volume":"81","author":"Ding","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.clgc.2024.102262_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106926","article-title":"The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo","volume":"196","author":"Pang","year":"2023","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.clgc.2024.102262_bib0032","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41418-024-01271-z","article-title":"Hypoxia-activated XBP1s recruits HDAC2-EZH2 to engage epigenetic suppression of \u0394Np63\u03b1 expression and promote breast cancer metastasis independent of HIF1\u03b1","volume":"31","author":"Chen","year":"2024","journal-title":"Cell Death Differ"},{"issue":"2","key":"10.1016\/j.clgc.2024.102262_bib0033","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s43018-022-00489-5","article-title":"Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer","volume":"4","author":"Zeleke","year":"2023","journal-title":"Nat Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2024.102262_bib0034","doi-asserted-by":"crossref","first-page":"e10541","DOI":"10.1002\/btm2.10541","article-title":"Quatramer\u2122 encapsulation of dual-targeted PI3-K\u03b4\/HDAC6 inhibitor, HSB-510, suppresses growth of breast cancer","volume":"8","author":"Tiwari","year":"2023","journal-title":"Bioeng Transl Med"},{"issue":"1","key":"10.1016\/j.clgc.2024.102262_bib0035","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s13046-020-01720-w","article-title":"HDAC3 deteriorates colorectal cancer progression via microRNA-296-3p\/TGIF1\/TGF\u03b2 axis","volume":"39","author":"Li","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clgc.2024.102262_bib0036","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/mc.23522","article-title":"Circular RNA ACACA negatively regulated p53-modulated mevalonate pathway to promote colorectal tumorigenesis via regulating miR-193a\/b-3p\/HDAC3 axis","volume":"62","author":"He","year":"2023","journal-title":"Mol Carcinog"},{"issue":"2","key":"10.1016\/j.clgc.2024.102262_bib0037","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/genes12020260","article-title":"Downregulation of cell cycle and checkpoint genes by class I HDAC inhibitors limits synergism with G2\/M checkpoint inhibitor MK-1775 in bladder cancer cells","volume":"12","author":"Hoffmann","year":"2021","journal-title":"Genes (Basel)"},{"issue":"1","key":"10.1016\/j.clgc.2024.102262_bib0038","first-page":"57","article-title":"Urinary expression of genes involved in DNA methylation and histone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria","volume":"18","author":"Lucca","year":"2019","journal-title":"Oncol Lett"},{"issue":"10","key":"10.1016\/j.clgc.2024.102262_bib0039","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.3390\/ijms20102599","article-title":"Characterization of histone deacetylase expression within in vitro and in vivo bladder cancer model systems","volume":"20","author":"Buckwalter","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.clgc.2024.102262_bib0040","first-page":"8","article-title":"miR-489-3p inhibits proliferation and migration of bladder cancer cells through downregulation of histone deacetylase 2","volume":"20","author":"Sun","year":"2020","journal-title":"Oncol Lett"},{"issue":"37","key":"10.1016\/j.clgc.2024.102262_bib0041","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.2174\/0929867324666170207142740","article-title":"HDACs and HDAC inhibitors in urothelial carcinoma - Perspectives for an antineoplastic treatment","volume":"24","author":"Pinkerneil","year":"2017","journal-title":"Curr Med Chem"},{"issue":"4","key":"10.1016\/j.clgc.2024.102262_bib0042","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/0008-5472.CAN-12-2730","article-title":"Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment","volume":"73","author":"Isaacs","year":"2013","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.clgc.2024.102262_bib0043","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.clgc.2024.102262_bib0044","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41698-024-00510-3","article-title":"Development of a stemness-related prognostic index to provide therapeutic strategies for bladder cancer","volume":"8","author":"Fu","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102262_bib0045","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1038\/s41467-024-47204-9","article-title":"Integration of pathologic characteristics, genetic risk and lifestyle exposure for colorectal cancer survival assessment","volume":"15","author":"Xin","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.clgc.2024.102262_bib0046","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(24)00076-7","article-title":"Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis","volume":"25","author":"Stassen","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102262_bib0047","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.bbcan.2017.04.004","article-title":"EMP1, EMP 2, and EMP3 as novel therapeutic targets in human cancer","volume":"1868","author":"Wang","year":"2017","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2024.102262_bib0048","first-page":"605","article-title":"Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K\/AKT\/mTOR signaling pathway","volume":"42","author":"Miao","year":"2019","journal-title":"Oncol Rep"},{"issue":"10","key":"10.1016\/j.clgc.2024.102262_bib0049","doi-asserted-by":"crossref","first-page":"17142","DOI":"10.1002\/jcb.28974","article-title":"EMP1 regulates cell proliferation, migration, and stemness in gliomas through PI3K-AKT signaling and CD44","volume":"120","author":"Wang","year":"2019","journal-title":"J Cell Biochem"},{"issue":"17","key":"10.1016\/j.clgc.2024.102262_bib0050","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.3390\/cancers15174420","article-title":"Differentially expressed genes, miRNAs and network models: a strategy to shed light on molecular interactions driving HNSCC tumorigenesis","volume":"15","author":"Arfin","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2024.102262_bib0051","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1313536","article-title":"An integrated analysis of bulk and single-cell sequencing data reveals that EMP1(+)\/COL3A1(+) fibroblasts contribute to the bone metastasis process in breast, prostate, and renal cancers","volume":"14","author":"Du","year":"2023","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.clgc.2024.102262_bib0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238466","article-title":"Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors","volume":"15","author":"Cha","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.clgc.2024.102262_bib0053","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178865","article-title":"Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN\/PI3K\/AKT pathway in lung cancer","volume":"12","author":"De Marco","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clgc.2024.102262_bib0054","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3892\/or.2020.7853","article-title":"Evaluating the biological functions of the prognostic genes identified by the Pathology Atlas in bladder cancer","volume":"45","author":"Chen","year":"2021","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clgc.2024.102262_bib0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41420-020-00295-x","article-title":"The prognostic value of six survival-related genes in bladder cancer","volume":"6","author":"Cheng","year":"2020","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.clgc.2024.102262_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.923768","article-title":"Identification of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with bladder cancer","volume":"13","author":"Yao","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.clgc.2024.102262_bib0057","article-title":"Comprehensive FGFR3 alteration-related transcriptomic characterization is involved in immune infiltration and correlated with prognosis and immunotherapy response of bladder cancer","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T15:19:31Z","timestamp":1753111171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324002325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1558767324002325"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102262","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transcriptome-Based Network Analysis Related to Histone Deacetylase Genes and Identified EMP1 as a Potential Biomarker for Prognosis in Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102262","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102262"}}